Mexico - Delayed Quote MXN

Mirum Pharmaceuticals, Inc. (MIRM.MX)

859.92

+3.86

+(0.45%)

At close: December 10 at 1:33:09 PM CST

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

FOSTER CITY, Calif., May 19, 2025--Mirum Pharmaceuticals Appoints Doug Sheehy, JD as Chief Legal Officer

Business Wire yesterday

MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif., May 14, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

Business Wire 6 days ago

MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 09, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 11 days ago

MIRM
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

FOSTER CITY, Calif., May 09, 2025--Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

Business Wire 11 days ago

MIRM
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Mirum Pharmaceuticals ( NASDAQ:MIRM ) First Quarter 2025 Results Key Financial Results Revenue: US$111.6m (up 61% from...

Simply Wall St. 11 days ago

MIRM
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

FOSTER CITY, Calif., May 07, 2025--Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire 13 days ago

MIRM
High Growth Tech Stocks To Watch In The US May 2025

The U.S. stock market is experiencing a notable upswing, with the S&P 500 on track for its longest winning streak since 2004, buoyed by strong employment data and potential trade talks between the U.S. and China. In this environment of optimism and recovery, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience in volatile conditions, adaptability to policy changes, and robust financial health amidst evolving economic landscapes.

Simply Wall St. 18 days ago

MIRM

BCRX

TRVG
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

FOSTER CITY, Calif., April 30, 2025--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Business Wire 20 days ago

MIRM
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

FOSTER CITY, Calif., April 28, 2025--Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Business Wire 22 days ago

MIRM
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif., April 14, 2025--Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire last month

MIRM
LIVMARLI Now Approved in Japan for ALGS and PFIC

FOSTER CITY, Calif., March 27, 2025--LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire last month

MIRM
Exploring 3 High Growth Tech Stocks in the US Market

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion within a stable and upward-trending market environment.

Simply Wall St. last month

ALKT

MIRM

INTA
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Last week, you might have seen that Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) released its yearly result to the...

Simply Wall St. 2 months ago

MIRM
Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Mirum Pharmaceuticals ( NASDAQ:MIRM ) Full Year 2024 Results Key Financial Results Revenue: US$336.9m (up 81% from FY...

Simply Wall St. 2 months ago

MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

FOSTER CITY, Calif., February 26, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update.

Business Wire 2 months ago

MIRM
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

FOSTER CITY, Calif., February 24, 2025--Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Business Wire 2 months ago

MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

FOSTER CITY, Calif., February 19, 2025--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Business Wire 2 months ago

MIRM
High Growth Tech Stocks in United States to Watch

The United States market has shown a positive trend, rising 1.2% over the last week and 24% over the past year, with earnings expected to grow by 15% annually. In this context of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability in an evolving market landscape.

Simply Wall St. 2 months ago

DOCN

KRYS

MIRM
Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high-growth tech stocks that can capitalize on such robust earnings growth potential becomes essential for investors seeking opportunities in a dynamic market environment.

Simply Wall St. 4 months ago

MSI

MIRM

ENFN
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

FOSTER CITY, Calif., January 13, 2025--Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Business Wire 4 months ago

MIRM

Performance Overview

Return	MIRM.MX	S&P 500 (^GSPC)
YTD	-4.70%	+1.00%
1-Year	+79.47%	+11.91%
3-Year	+130.00%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mirum Pharmaceuticals, Inc. (MIRM.MX)

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks To Watch In The US May 2025

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

LIVMARLI Now Approved in Japan for ALGS and PFIC

Exploring 3 High Growth Tech Stocks in the US Market

Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report

Mirum Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

High Growth Tech Stocks in United States to Watch

Exploring Three High Growth Tech Stocks in the United States

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Performance Overview